These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 8654197

  • 1. Minimal effects of two aldose reductase inhibitors, AL-1576 and AL-4114, after subacute topical-ocular dosing on xenobiotic biotransformation in rabbits.
    Sastry SG, Sanders RA, Veltman JC, Watkins JB.
    Drug Metab Dispos; 1995 Oct; 23(10):1094-8. PubMed ID: 8654197
    [Abstract] [Full Text] [Related]

  • 2. Comparative study of phase II biotransformation in rabbit ocular tissues.
    Watkins JB, Wirthwein DP, Sanders RA.
    Drug Metab Dispos; 1991 Oct; 19(3):708-13. PubMed ID: 1680641
    [Abstract] [Full Text] [Related]

  • 3. Effects of aldose reductase inhibitors on antioxidant defense in rat and rabbit liver.
    Thomas T, Rauscher F, Sanders R, Veltman J, Watkins JB.
    Toxicol Sci; 2000 Jan; 53(1):145-9. PubMed ID: 10653532
    [Abstract] [Full Text] [Related]

  • 4. Determination of aldose reductase activity in the eye by localized magnetic resonance spectroscopy.
    Lizak MJ, Mori K, Kador PF.
    J Ocul Pharmacol Ther; 2001 Oct; 17(5):475-83. PubMed ID: 11765152
    [Abstract] [Full Text] [Related]

  • 5. [Correction of diabetic neuropathies using aldose reductase inhibitors and pikamilon].
    Kuchmerovskaia TM, Parkhomets PK, Donchenko GV, Obrosova IG, Klimenko AP, Kuchmerovskiĭ NA, Pakirbaeva LV, Efimov AS.
    Vopr Med Khim; 1998 Oct; 44(6):559-64. PubMed ID: 10599142
    [Abstract] [Full Text] [Related]

  • 6. Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
    Griffin BW, McNatt LG, Chandler ML, York BM.
    Metabolism; 1987 May; 36(5):486-90. PubMed ID: 3106757
    [Abstract] [Full Text] [Related]

  • 7. AL-1576, an aldose reductase inhibitor (ARI), did not prevent the decrease of norepinephrine turnover in diabetic rats.
    Yen TT, Fuller RW, Broderick CL, Hemrick-Luecke SK, Perry KW.
    Res Commun Chem Pathol Pharmacol; 1988 Aug; 61(2):257-60. PubMed ID: 3141993
    [Abstract] [Full Text] [Related]

  • 8. Iris vasculopathy in galactose-fed rats.
    Caspers-Velu LE, Wadhwani KC, Rapoport SI, Kador PF.
    Exp Eye Res; 1999 Feb; 68(2):211-21. PubMed ID: 10068486
    [Abstract] [Full Text] [Related]

  • 9. Diabetic-like corneal sensitivity loss in galactose-fed rats ameliorated with aldose reductase inhibitors.
    Jacot JL, Hosotani H, Glover JP, Lois N, Robison WG.
    J Ocul Pharmacol Ther; 1998 Apr; 14(2):169-80. PubMed ID: 9572543
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of naphthalene cataract in rats by aldose reductase inhibitors.
    Lou MF, Xu GT, Zigler S, York B.
    Curr Eye Res; 1996 Apr; 15(4):423-32. PubMed ID: 8670742
    [Abstract] [Full Text] [Related]

  • 11. A new approach against sugar cataract through aldose reductase inhibitors.
    Banditelli S, Boldrini E, Vilardo PG, Cecconi I, Cappiello M, Dal Monte M, Marini I, Del Corso A, Mura U.
    Exp Eye Res; 1999 Nov; 69(5):533-8. PubMed ID: 10548473
    [Abstract] [Full Text] [Related]

  • 12. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
    Nakano T, Petrash JM.
    Biochemistry; 1996 Aug 27; 35(34):11196-202. PubMed ID: 8780524
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and efficacy of structurally related spirohydantoin and spirosuccinimide aldose reductase inhibitors.
    Park YH, Barker R, Griffin B, Barratt D, DuPriest M, Brazzell K, York B, Mayer P.
    Xenobiotica; 1992 May 27; 22(5):543-50. PubMed ID: 1413869
    [Abstract] [Full Text] [Related]

  • 14. Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats.
    Kador PF, Inoue J, Secchi EF, Lizak MJ, Rodriguez L, Mori K, Greentree W, Blessing K, Lackner PA, Sato S.
    Exp Eye Res; 1998 Aug 27; 67(2):203-8. PubMed ID: 9733586
    [Abstract] [Full Text] [Related]

  • 15. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
    Saraswat M, Muthenna P, Suryanarayana P, Petrash JM, Reddy GB.
    Asia Pac J Clin Nutr; 2008 Aug 27; 17(4):558-65. PubMed ID: 19114390
    [Abstract] [Full Text] [Related]

  • 16. Drug metabolizing enzyme expression in rat choroid plexus: effects of in vivo xenobiotics treatment.
    Gradinaru D, Minn AL, Artur Y, Minn A, Heydel JM.
    Arch Toxicol; 2009 Jun 27; 83(6):581-6. PubMed ID: 19023562
    [Abstract] [Full Text] [Related]

  • 17. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
    Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M.
    Diabetes; 2006 Oct 27; 55(10):2757-62. PubMed ID: 17003340
    [Abstract] [Full Text] [Related]

  • 18. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.
    Negoro T, Murata M, Ueda S, Fujitani B, Ono Y, Kuromiya A, Komiya M, Suzuki K, Matsumoto J.
    J Med Chem; 1998 Oct 08; 41(21):4118-29. PubMed ID: 9767647
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of the aldose reductase inhibitor imirestat following topical ocular administration.
    Brazzell RK, Wooldridge CB, Hackett RB, McCue BA.
    Pharm Res; 1990 Feb 08; 7(2):192-8. PubMed ID: 2106677
    [Abstract] [Full Text] [Related]

  • 20. Quantitative structure and aldose reductase inhibitory activity relationship of 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone derivatives.
    Ko K, Won Y.
    Bioorg Med Chem; 2005 Mar 01; 13(5):1445-52. PubMed ID: 15698760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.